Stephane Supiot

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 292 publications

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.

Enzalutamide Monotherapy for the Treatment of Prostate Cancer with High-Risk Biochemical Recurrence: EMBARK Secondary End Points: Erratum.

Journal: The Journal of urology

Published: July 09, 2026

Evidence Thresholds for Novel Therapeutic Strategies in Prostate Cancer: A Consensus Statement from the Prostate Cancer Committee of the French Urological Association.

Evidence Thresholds for Novel Therapeutic Strategies in Prostate Cancer: A Consensus Statement from the Prostate Cancer Committee of the French Urological Association.

Journal: The French journal of urology

Published: June 29, 2026

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

Journal: European urology

Published: May 11, 2026

OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial.

OLIGOPELVIS 2-GETUG P12- elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: March 03, 2026

Erratum to "External beam radiotherapy for prostatic cancers: 2025 update" [Cancer Radiother 29 (2025) 104777].

Erratum to "External beam radiotherapy for prostatic cancers: 2025 update" [Cancer Radiother 29 (2025) 104777].

Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique

Published: February 17, 2026

Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer.

Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer.

Journal: European urology oncology

Published: February 13, 2026

SPINAL: study protocol for a multicenter non-inferiority trial evaluating reduce vertebral irradiation volumes in palliative radiotherapy for spinal bone metastases on analgesic efficacy.

SPINAL: study protocol for a multicenter non-inferiority trial evaluating reduce vertebral irradiation volumes in palliative radiotherapy for spinal bone metastases on analgesic efficacy.

Journal: BMC cancer

Published: January 23, 2026

Cumulative dose analysis following elective pelvis re-irradiation at junction with primary prostate radiotherapy from the OLIGOPELVIS GETUG P07 trial.

Cumulative dose analysis following elective pelvis re-irradiation at junction with primary prostate radiotherapy from the OLIGOPELVIS GETUG P07 trial.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: January 14, 2026

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.

Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points.

Journal: The Journal of urology

Published: December 05, 2025

A review of clinical trial radiotherapy quality assurance: value, evolution and lessons.

A review of clinical trial radiotherapy quality assurance: value, evolution and lessons.

Journal: Clinical and translational radiation oncology

Published: November 25, 2025

Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).

Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).

Journal: Future oncology (London, England)

Published: November 11, 2025

Reirradiation: A new therapeutic paradigm in oncology

Reirradiation: A new therapeutic paradigm in oncology

Journal: Bulletin du cancer

Published: October 21, 2025

Showing 1-12 of 292

Last Updated: 09/26/2026